The recoveries surged to 15,35,743 with a record 54,859 more people recuperating in the past 24 hours, taking the recovery rate to 69.33 per cent. The case fatality rate has dropped to about 2 per cent, the govt said.
India's tally of COVID-19 cases rose to 1,08,26,363 with 12,059 new infections being reported in a day, while the daily deaths fell below 100 for the third time this month, according to the Union Health Ministry data updated on Sunday.
A total of 3,00,41,400 samples have been tested until August 16 with 7,31,697 samples being tested on Sunday, the Indian Council of Medical Research said.
Disgruntled Janata Dal-United leader Upendra Kushwaha on Monday resigned from Chief Minister Nitish Kumar's party, less than two years after returning to the party, and announced formation of the 'Rashtriya Loktantrik Janata Dal'.
In Jaipur, the combination of lopinavir and ritonavir, both second-line HIV drugs, was administered was administered on an elderly Italian couple undergoing treatment for Covid-19 at the SMS Hospital.
According to these experts, a monkeypox outbreak can effectively be tackled by strong surveillance.
The active cases comprise 0.03 per cent of the total infections, while the national COVID-19 recovery rate remained at 98.76 per cent, the ministry said.
India saw a single day rise of 4,184 coronavirus infections taking the total tally of COVID-19 cases to 4,29,80,067, while the active cases dipped to 44,488, according to the Union Health Ministry data updated on Thursday.
The COVID-19 case fatality rate has further declined to 1.52 per cent.
The death toll climbed to 5,21,736 with 26 fresh fatalities, the data updated at 8 am stated.
Nearly half of all coronavirus patients in the country have been cured, taking the recovery rate to over 48 per cent.
A person who has cancer and doesn't have any health insurance will find it difficult to buy a regular hospitalisation cover. An indemnity-based cancer plan may cover them.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances